Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.…
/C O R R E C T I O N - Edgewise Therapeutics/
Edgewise Therapeutics (NASDAQ: EWTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 133 employees.
The shares were at 39.90 USD on 20 November 2026, up 132.5% over 52 weeks. Its 52-week range is 16.98 USD to 48.78 USD: the price is 18.2% below the high and 135.1% above the low.
At a market capitalisation of 4.37B USD, it trades at 4.8 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 86% for EWTX.
Edgewise Therapeutics reports return on equity of -32.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.74B USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 55.42 USD is 38.9% above the current price. The next earnings report is expected on 25 February 2027.